STOCK Fcgr1tm1Jsv/Cnrm
| Status | Available to order |
| EMMA ID | EM:02540 |
| International strain name | STOCK Fcgr1tm1Jsv/Cnrm |
| Alternative name | CD64 KO on C57Bl6 |
| Strain type | Targeted Mutant Strains : Knock-out |
| Allele/Transgene symbol | Fcgr1tm1Jsv, |
| Gene/Transgene symbol | Fcgr1 |
Information from provider
| Provider | Joseph Verbeek |
| Provider affiliation | Human Genetics, Leiden University Medical Center (LUMC) |
| Genetic information | Deletion of 3'-part of promoter, exon 1 (L1 domain), exon 2 (L2 domain) and 5'-part of exon 3 (ligand binding EC1 domain), replaced by PGK-hygromycin resistance cassette. |
| Phenotypic information | Impaired IgG2a antibody effector pathways. |
| Breeding history | Generated with E14 129P2 ES cell line; F1-F2: C57BL/6 F3-F4 BALB/c F5-F12: C57BL/6 |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | yes |
Information from EMMA
| Archiving centre | CNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy |
Literature references
- FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection.;Ioan-Facsinay A, de Kimpe S J, Hellwig S M M, van Lent P L, Hofhuis F M A, van Ojik H H, Sedlik C, da Silveira S A, Gerber J, de Jong Y F, Roozendaal R, Aarden L A, van den Berg W B, Saito T, Mosser D, Amigorena S, Izui S, van Ommen G J B, van Vugt M, van de Winkel J G J, Verbeek J S, ;2002;Immunity;16;391-402; 11911824